Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | EDNRA | P25101 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16208746 | 1.00 | PTGS1 (0.55) | PTGS1NR1I2ADRA1ALMNABLM | |
| SCHEMBL5279500 | 1.00 | PTGS1 (0.55) | PTGS1NR1I2ADRA1ALMNABLM | |
| Acetic Acid SCHEMBL10942103 | 0.96 | PTGS1 (0.51) | PTGS1NR1I2ADRA1ALMNABLM | |
| Acetic Acid SCHEMBL10875129 | 0.96 | PTGS1 (0.51) | PTGS1NR1I2ADRA1ALMNABLM | |
| SCHEMBL24517929 | 0.91 | PTGS1 (0.60) | PTGS1NR1I2ADRA1ALMNABLM | |
| SCHEMBL16208754 | 0.86 | EDNRA (0.45) | PTGS1LMNAMAPK9PTGS2MAPK1 | |
| SCHEMBL5281154 | 0.86 | MAPK9 (0.52) | PTGS1MAPK9PTGS2MAPK1ALDH1A1 | |
| SCHEMBL8874548 | 0.86 | MAPK9 (0.52) | PTGS1MAPK9PTGS2MAPK1ALDH1A1 | |
| SCHEMBL7990464 | 0.84 | MAPK9 (0.54) | PTGS1MAPK9PTGS2MAPK1ALDH1A1 | |
| SCHEMBL18076242 | 0.82 | EDNRA (0.51) | ALDH1A1EDNRAKMT2AMEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920342-B2 | Process for the preparation of Droxidopa | DIVI'S LABORATORIES LIMITED | 2018-03-20 | — | — | US | claimed |
| US-20170335357-A1 | PROCESS FOR THE PREPARATION OF DROXIDOPA | DIVI'S LABORATORIES LIMITED (IN) | 2017-11-23 | — | — | US | claimed |
| US-4562263-A | HYPOTENSIVE AND HYDERTENSIVE AGENTS, ANTIDEPRESSANTS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-12-31 | — | — | US | claimed |
| JP-2225480-A | — | — | None | — | — | JP | disclosed |
| CN-113816943-B | Resolution method of droxidopa key intermediate | 重庆圣华曦药业股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-113773297-B | Resolution method of droxidopa key intermediate | 重庆圣华曦药业股份有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-9920342-B2 | Process for the preparation of Droxidopa | DIVI'S LABORATORIES LIMITED | 2018-03-20 | — | — | US | disclosed |
| US-9920342-B2 | Process for the preparation of Droxidopa | DIVI'S LABORATORIES LIMITED | 2018-03-20 | — | — | US | disclosed |
| US-20170335357-A1 | PROCESS FOR THE PREPARATION OF DROXIDOPA | DIVI'S LABORATORIES LIMITED (IN) | 2017-11-23 | — | — | US | disclosed |
| US-20170335357-A1 | PROCESS FOR THE PREPARATION OF DROXIDOPA | DIVI'S LABORATORIES LIMITED (IN) | 2017-11-23 | — | — | US | disclosed |
| US-20130253061-A1 | METHOD OF DROXIDOPA SYNTHESIS | CHELSEA THERAPEUTICS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2013142093-A1 | METHOD FOR THE SYNTHESIS OF DROXIDOPA | CHELSEA THERAPEUTICS, INC. (US) | 2013-09-26 | — | — | WO | disclosed |
| JP-H02225480-A | PRODUCTION OF RACEMIC MODIFICATION AND EPIMERIC ISOMER | SUMITOMO PHARMACEUT CO LTD | 1990-09-07 | — | — | JP | disclosed |
| EP-0141613-B1 | A PROCESS FOR PRODUCING AN OPTICALLY ACTIVE 3-(3,4-DIHYDROXPHENYL) SERINE AND A PROTECED DERIVATIVE THEREOF | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1989-02-01 | — | — | EP | disclosed |
| EP-0204481-A2 | Process for optically active threo-3-(3,4-methylenedioxyphenyl) serine | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1986-12-10 | — | — | EP | disclosed |
| US-4562263-A | HYPOTENSIVE AND HYDERTENSIVE AGENTS, ANTIDEPRESSANTS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-12-31 | — | — | US | disclosed |
| EP-0084928-B1 | PROCESS FOR PRODUCING THREO-3-(3,4-DIHYDROXYPHENYL)SERINE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-09-11 | — | — | EP | disclosed |
| EP-0128684-A1 | Process for producing 3-(3,4-dihydroxyphenyl) serine | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1984-12-19 | — | — | EP | disclosed |
| US-4480109-A | Process for producing threo-3-(3,4-dihydroxyphenyl)serine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-10-30 | — | — | US | disclosed |
| EP-0084928-A1 | Process for producing threo-3-(3,4-dihydroxyphenyl)serine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130253061-A1 | METHOD OF DROXIDOPA SYNTHESIS | DDO, DAO, COMT | PTGS1 4157/4885NR1I2 4486/4885ADRA1A 296/4885 |
| US-20170335357-A1 | PROCESS FOR THE PREPARATION OF DROXIDOPA | DAO, DDO, DNPEP | PTGS1 4025/4885NR1I2 4717/4885ADRA1A 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.